BibTex RIS Cite

EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C

Year 2011, Volume: 8 Issue: 1, 7 - 12, 01.03.2011

Mustafa Güçlü Mustafa Güçlü Hakan Sakallı Tolga Yakar Nurzen Sezgin Murat Gülşen

Abstract

Keywords

-

References

  • Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
  • Lfkowitch JH, Schiff ER, Davis GL, et al. Pathological di- agnosis of chranic hepatitis C: a multicenter camparative study with chronic hepatitis B. Gasroenterology 1993; 104:595-603.
  • Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of chranic hepatitis C. Hepatology 1992;15:567-71.
  • Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cellsvia low-density lipoprotein receptor. Proc Natl Acad Sei USA 1996;96:12766-71.
  • Monazahian M, Bohme 1, Bonk S, et al. Low densty lipo- protein receptor as a candidate receptorfor hepatitis C virus. J Med Virol 1999;57:223-9.
  • Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to collular lipid storage droplet. Proc Natl Acad Sci USA 1997;94:1200-5.
  • Sabila A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein Aıı and its secretion is modulated by fibrates. Hepatolgy 1999;30:1064-76.
  • Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatiits C virus induced hypobetalipopro- teinemia: a possible mechanism for steatosis in chronic hepatitis. J Hepatol 2001;34:428-34.
  • Kyoji Moriya et all. Serum lipid profilo of patients with genotype 1b hepatitis C viral infection in Japan. Hepatology Research 2003; 25: 371-76.
  • Parlemuter G, Sabila A, Letteron P, et al. Hepatitis C vi- rus core protein inhibits triglyceride-transfer protein ac- tivity and very low-density lipoprotein secration: amodel of viral-related steatosis. FASEB J 2002;16:185-94.
  • Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Steals B. Negative regulation of the human apolipo- protein A-1 promoter by fibrates can be atteunated by the interaction of the proxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-8.
  • Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the proxisome proliferator-activated receptor. J Clin Insevt 1995;96:741-50.
  • Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection : Prevalence and clini- cal correlation. J Gastroenterol Hepatol 2001;16:190-5.
  • Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte ste- atosis ia a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
  • Kumar D, Farrel GC, Fung C, et al. Hematitis C virus gen- otype 3 is cytopathic to hepatocytes.Genotype specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
  • Poynard T, Ratziu V, McHutchison J. et al. Effect of treat- ment with peginterferon or interferon alfa-2b and riba- virin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
  • Adinolfi LE, Gambardella A, Tripodi MF, Utili R, Ruggiero G, Andreana A. Steatosis accelerates the progession of liver damage of chronic hepatitis C patients and corre- lates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
  • Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C virus RNA and core antigen concentra- tions and determination of whether levels are associated with liver histology or affected by specimen stroge time. J Clin Microbiol 2002;40:4224-9.
  • Bressler BL, Guindi M, Tomlinson G, Heatcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
  • Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: Can weight reduction improve therapeutic efficacy. J Hepetol 2001;35:432-3.

EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C

Year 2011, Volume: 8 Issue: 1, 7 - 12, 01.03.2011

Mustafa Güçlü Mustafa Güçlü Hakan Sakallı Tolga Yakar Nurzen Sezgin Murat Gülşen

Abstract

-

Keywords

-

References

  • Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
  • Lfkowitch JH, Schiff ER, Davis GL, et al. Pathological di- agnosis of chranic hepatitis C: a multicenter camparative study with chronic hepatitis B. Gasroenterology 1993; 104:595-603.
  • Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of chranic hepatitis C. Hepatology 1992;15:567-71.
  • Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cellsvia low-density lipoprotein receptor. Proc Natl Acad Sei USA 1996;96:12766-71.
  • Monazahian M, Bohme 1, Bonk S, et al. Low densty lipo- protein receptor as a candidate receptorfor hepatitis C virus. J Med Virol 1999;57:223-9.
  • Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to collular lipid storage droplet. Proc Natl Acad Sci USA 1997;94:1200-5.
  • Sabila A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein Aıı and its secretion is modulated by fibrates. Hepatolgy 1999;30:1064-76.
  • Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatiits C virus induced hypobetalipopro- teinemia: a possible mechanism for steatosis in chronic hepatitis. J Hepatol 2001;34:428-34.
  • Kyoji Moriya et all. Serum lipid profilo of patients with genotype 1b hepatitis C viral infection in Japan. Hepatology Research 2003; 25: 371-76.
  • Parlemuter G, Sabila A, Letteron P, et al. Hepatitis C vi- rus core protein inhibits triglyceride-transfer protein ac- tivity and very low-density lipoprotein secration: amodel of viral-related steatosis. FASEB J 2002;16:185-94.
  • Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Steals B. Negative regulation of the human apolipo- protein A-1 promoter by fibrates can be atteunated by the interaction of the proxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-8.
  • Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the proxisome proliferator-activated receptor. J Clin Insevt 1995;96:741-50.
  • Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection : Prevalence and clini- cal correlation. J Gastroenterol Hepatol 2001;16:190-5.
  • Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte ste- atosis ia a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
  • Kumar D, Farrel GC, Fung C, et al. Hematitis C virus gen- otype 3 is cytopathic to hepatocytes.Genotype specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
  • Poynard T, Ratziu V, McHutchison J. et al. Effect of treat- ment with peginterferon or interferon alfa-2b and riba- virin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
  • Adinolfi LE, Gambardella A, Tripodi MF, Utili R, Ruggiero G, Andreana A. Steatosis accelerates the progession of liver damage of chronic hepatitis C patients and corre- lates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
  • Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C virus RNA and core antigen concentra- tions and determination of whether levels are associated with liver histology or affected by specimen stroge time. J Clin Microbiol 2002;40:4224-9.
  • Bressler BL, Guindi M, Tomlinson G, Heatcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
  • Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: Can weight reduction improve therapeutic efficacy. J Hepetol 2001;35:432-3.
There are 20 citations in total.

Details

Primary Language English
Journal Section Original Articles
Authors

Mustafa Güçlü This is me

Mustafa Güçlü This is me

Hakan Sakallı This is me

Tolga Yakar This is me

Nurzen Sezgin This is me

Murat Gülşen This is me

Publication Date March 1, 2011
Published in Issue Year 2011 Volume: 8 Issue: 1

Cite

APA Güçlü, M., Güçlü, M., Sakallı, H., Yakar, T., et al. (2011). EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C. European Journal of General Medicine, 8(1), 7-12.
AMA Güçlü M, Güçlü M, Sakallı H, Yakar T, Sezgin N, Gülşen M. EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C. European Journal of General Medicine. March 2011;8(1):7-12.
Chicago Güçlü, Mustafa, Mustafa Güçlü, Hakan Sakallı, Tolga Yakar, Nurzen Sezgin, and Murat Gülşen. “EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C”. European Journal of General Medicine 8, no. 1 (March 2011): 7-12.
EndNote Güçlü M, Güçlü M, Sakallı H, Yakar T, Sezgin N, Gülşen M (March 1, 2011) EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C. European Journal of General Medicine 8 1 7–12.
IEEE M. Güçlü, M. Güçlü, H. Sakallı, T. Yakar, N. Sezgin, and M. Gülşen, “EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C”, European Journal of General Medicine, vol. 8, no. 1, pp. 7–12, 2011.
ISNAD Güçlü, Mustafa et al. “EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C”. European Journal of General Medicine 8/1 (March 2011), 7-12.
JAMA Güçlü M, Güçlü M, Sakallı H, Yakar T, Sezgin N, Gülşen M. EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C. European Journal of General Medicine. 2011;8:7–12.
MLA Güçlü, Mustafa et al. “EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C”. European Journal of General Medicine, vol. 8, no. 1, 2011, pp. 7-12.
Vancouver Güçlü M, Güçlü M, Sakallı H, Yakar T, Sezgin N, Gülşen M. EVALUATION OF SERUM LIPID PROFILE IN TURKISH PATIENTS WITH CHRONIC HEPATITIS C. European Journal of General Medicine. 2011;8(1):7-12.